Advanced Enzyme Tech cash flow

Latest FY26

Cash from operations: ₹157cr+10.0% on FY25
Capital spending: ₹52.4cr+50.6% on FY25
Free cash flow: ₹104cr−3.1% on FY25
Cash from financing: −₹70.4cr−₹72.5 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	40.1	36.6	35.2	35.0
	—	0.0	−6.1	0.0	0.0
	—	−9.7	−8.2	−10.8	2.2
	—	4.9	3.4	0.0	0.0
	—	−0.4	−0.1	−0.1	−0.1
	—	−0.5	1.5	18.6	4.8
	—	0.5	−0.2	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	−16.2	−7.8	−23.8	0.8
	—	−25.9	−17.7	0.9	−10.0
	—	−0.7	11.4	0.2	1.8
	—	−0.2	0.0	−0.3	−0.6
	—	−1.4	1.8	−2.0	0.0
	—	0.6	0.3	−1.1	1.5
	—	19.5	1.2	−3.9	6.0
	—	2.7	1.0	−0.3	0.0
	—	1.2	−3.2	0.2	1.2
	—	0.0	0.0	0.0	−0.2
	—	−9.0	1.0	0.0	0.0
Cash from operating activities
	231	233	187	188	140
	—	5.4	14.8	12.8	42.6
	—	238	202	201	183
	—	−18.7	0.0	−13.0	−8.4
	—	−2.6	0.0	−2.9	−2.4
	—	65.1	59.7	49.2	36.6
	—	157	142	141	140
Cash from investing activities
	—	52.2	33.8	42.3	38.1
	—	0.1	1.0	0.1	0.1
	—	0.4	0.5	0.2	0.3
	—	0.0	0.0	5.0	0.0
	—	18.2	9.9	12.9	7.9
	—	−40.4	−64.8	−30.4	−268
	—	−74.1	−89.1	−64.6	−298
Cash from financing activities
	—	1.0	0.4	0.0	0.1
	—	0.0	−5.8	0.0	0.0
	—	1.0	−2.2	−12.1	0.3
	—	0.0	0.0	6.0	6.5
	—	2.4	3.3	2.9	2.4
	—	59.8	59.0	56.7	12.5
	—	−8.1	−7.0	−5.6	−4.2
	—	−70.4	−72.5	−59.2	−25.8
	—	12.3	−19.1	17.5	−184
	—	2.3	−0.4	−0.2	12.7
	—	14.5	−19.5	17.3	−171
	—	—	—	114	96.4
Reference items
	224	229	194	204	156
	29.8%	30.7%	30.5%	32.8%	28.9%
	104	104	108	99.0	102
	—	101	101	108	—
	₹9.33	₹9.33	₹9.62	₹8.85	₹9.13
	26.74×	—	—	—	—
	—	0.90×	1.06×	1.03×	1.35×
	—	65.1	59.7	49.2	36.6
	—	2.4	3.3	2.9	2.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ADVENZYMES₹249.45

Advanced Enzyme Tech Ltd.

· Pharma & Health

₹ CrorePeersAARTIPHARM AARTIDRUGS AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹2,792 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	35.0	35.2	36.6	40.1	—
+ Finance Costs	0.0	0.0	-6.1	0.0	—
+ Fair Value (Gains) / Losses	2.2	-10.8	-8.2	-9.7	—
+ Share-based Payments	0.0	0.0	3.4	4.9	—
+ Unrealised FX (Gain) / Loss	-0.1	-0.1	-0.1	-0.4	—
+ Other Non-cash Items	4.8	18.6	1.5	-0.5	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-0.2	0.5	—
+ Other Reconciling Items	0.0	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	0.8	-23.8	-7.8	-16.2	—
+ Trade Receivables — Current	-10.0	0.9	-17.7	-25.9	—
+ Other Financial Assets — Current	1.8	0.2	11.4	-0.7	—
+ Other Financial Assets — Non-current	-0.6	-0.3	0.0	-0.2	—
+ Other Current Assets	0.0	-2.0	1.8	-1.4	—
+ Other Non-current Assets	1.5	-1.1	0.3	0.6	—
+ Trade Payables — Current	6.0	-3.9	1.2	19.5	—
+ Other Financial Liabilities — Current	0.0	-0.3	1.0	2.7	—
+ Other Current Liabilities	1.2	0.2	-3.2	1.2	—
+ Other Non-current Liabilities	-0.2	0.0	0.0	0.0	—
+ Provisions — Current	0.0	0.0	1.0	-9.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	140.4	187.8	187.4	232.5	231.2
+ Total Adjustments (incl. Working Capital)	42.6	12.8	14.8	5.4	—
Cash from Operations (pre-tax)	183.0	200.6	202.2	237.9	—
+ Interest Received — Operating	-8.4	-13.0	0.0	-18.7	—
+ Interest Paid — Operating	-2.4	-2.9	0.0	-2.6	—
+ Income Taxes Paid	36.6	49.2	59.7	65.1	—
Cash from Operating Activities	140.4	141.4	142.5	156.8	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	38.1	42.3	33.8	52.2	—
+ Acq of Intangible Assets	0.1	0.1	1.0	0.1	—
+ Disp of Fixed Assets	0.3	0.2	0.5	0.4	—
+ Acq of Intangibles under Development	0.0	5.0	0.0	0.0	—
+ Interest Received — Investing	7.9	12.9	9.9	18.2	—
+ Other Inflows / (Outflows) — Investing	-268.1	-30.4	-64.8	-40.4	—
Cash from Investing Activities	-298.2	-64.6	-89.1	-74.1	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.1	0.0	0.4	1.0	—
+ Proceeds from Borrowings	0.0	0.0	-5.8	0.0	—
+ Repayment of Borrowings	0.3	-12.1	-2.2	1.0	—
+ Payment of Lease Liabilities	6.5	6.0	0.0	0.0	—
+ Interest Paid	2.4	2.9	3.3	2.4	—
+ Dividends Paid	12.5	56.7	59.0	59.8	—
+ Other Inflows / (Outflows) — Financing	-4.2	-5.6	-7.0	-8.1	—
Cash from Financing Activities	-25.8	-59.2	-72.5	-70.4	—
Net Changes in Cash (pre-FX)	-183.6	17.5	-19.1	12.3	—
+ Effect of FX Rate Changes on Cash	12.7	-0.2	-0.4	2.3	—
Net Changes in Cash	-171.0	17.3	-19.5	14.5	—
Closing Cash	96.4	113.8	—	—	—
Reference Items
EBITDA	156.4	204.5	194.4	229.1	223.6
EBITDA Margin %	28.94	32.77	30.53	30.72	29.83
Free Cash Flow (CFO − Capex)	102.2	99.0	107.7	104.4	104.4
Free Cash Flow to Equity	—	108.0	100.8	101.0	—
Free Cash Flow per Basic Share	9.13	8.85	9.62	9.33	9.33
Price to Free Cash Flow	—	—	—	—	26.74
Cash Flow to Net Income	1.35	1.03	1.06	0.90	—
Cash Paid for Taxes	36.6	49.2	59.7	65.1	—
Cash Paid for Interest	2.4	2.9	3.3	2.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.